Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
- Conditions
- Liver Transplantation
- Interventions
- Drug: TAC withdrawal
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03596970
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- Conditions
- FLT3-mutated Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03591510
- Locations
- 🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States
🇺🇸Miami Children s Hospital, Miami, Florida, United States
🇹🇷Novartis Investigative Site, Istanbul, Turkey
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Placebo 2 mL auto-injectorDrug: Placebo 1 mL prefilled syringe
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT03589885
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Biological: OmalizumabBiological: LigelizumabOther: Placebo
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1072
- Registration Number
- NCT03580369
- Locations
- 🇹🇷
Novartis Investigative Site, Samsun, Turkey
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1078
- Registration Number
- NCT03580356
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Medical Resch of Arizona-Div of Allergy Asthma and Immunology, Scottsdale, Arizona, United States
🇺🇸Atria Clinical Research Asthma and Allergy Institute, Little Rock, Arkansas, United States
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
- Conditions
- CMLLeukemia, Myeloid ChronicHematologic DiseasesChronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT03578367
- Locations
- 🇺🇸
Georgia Regents University, Augusta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇬🇧Novartis Investigative Site, Oxford, United Kingdom
Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: ianalumab
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT03574545
- Locations
- 🇯🇴
Novartis Investigative Site, Amman, Jordan
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 331
- Registration Number
- NCT03570892
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Medical Center, San Francisco, California, United States
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT03568461
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸UCSF Medical Center, San Francisco, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
- Conditions
- Multiple Sclerosis
- Interventions
- Combination Product: ofatumumab with AICombination Product: ofatumumab with PRF
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 284
- Registration Number
- NCT03560739
- Locations
- 🇪🇸
Novartis Investigative Site, Castilleja de la cuesta, Sevilla, Spain